Biocon, Ltd.’s early commentary on the way things are shaping in the US Humira biosimilar market reflected what some other key players have been saying – uptake hasn’t been rapid and the payer landscape is still developing.
At the earnings call for the fiscal first quarter, Kiran Mazumdar-Shaw, chairperson, Biocon and Biocon Biologics Ltd (BBL), referred to...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
